论文部分内容阅读
目的探讨肺表面活性物质(PS)稀释剂肺泡灌洗治疗新生儿胎粪吸入综合征(MAS)的疗效及安全性。方法 MAS患儿58例分为肺泡灌洗组(A组,25例)和常规治疗组(B组,33例)。ELISA法检测治疗前和治疗后24、72h两组支气管肺泡灌洗液(BALF)中肺表面活性蛋白(SP)-A、SP-D及血管内皮生长因子(VEGF)的含量,记录相关呼吸指标。结果治疗后,A组BALF中SP-A、SP-D含量高于B组(P<0.05);而VEFG含量低于B组(P<0.05)。A组机械通气时间和氧暴露时间为(79.0±19.6)h和(105.6±28.8)h,均少于B组的(111.9±26.1)h和(139.2±22.5)h(P<0.05)。结论 PS稀释剂肺泡灌洗治疗MAS可抑制肺部炎症,减轻肺损伤,改善预后。
Objective To investigate the efficacy and safety of pulmonary surfactant (PS) diluent alveolar lavage for neonatal meconium aspiration syndrome (MAS). Methods Fifty-eight children with MAS were divided into bronchoalveolar lavage group (A group, 25 cases) and conventional treatment group (B group, 33 cases). The levels of SP-A, SP-D and VEGF in bronchoalveolar lavage fluid (BALF) were measured before and 24 and 72 hours after treatment by ELISA. The relative respiratory index . Results After treatment, the content of SP-A and SP-D in BALF in group A was higher than that in group B (P <0.05), while the content of VEFG in group B was lower than that in group B (P <0.05). The duration of mechanical ventilation and oxygen exposure in group A were (79.0 ± 19.6) h and (105.6 ± 28.8) h, respectively, less than that in group B (111.9 ± 26.1 h and 139.2 ± 22.5 h, P <0.05). Conclusions PS diluent alveolar lavage treatment MAS can inhibit lung inflammation, reduce lung injury and improve prognosis.